Drug Delivery

Volume 197 of the series Handbook of Experimental Pharmacology pp 55-86


Nanoparticle Technologies for Cancer Therapy

  • Frank Alexis
  • , Eric M. Pridgen
  • , Robert Langer
  • , Omid C. FarokhzadAffiliated withHarvard Medical School, Laboratory of Nanomedicine and Biomaterials, Brigham and Women’s Hospital Email author 

* Final gross prices may vary according to local VAT.

Get Access


Nanoparticles as drug delivery systems enable unique approaches for cancer treatment. Over the last two decades, a large number of nanoparticle delivery systems have been developed for cancer therapy, including organic and inorganic materials. Many liposomal, polymer–drug conjugates, and micellar formulations are part of the state of the art in the clinics, and an even greater number of nanoparticle platforms are currently in the preclinical stages of development. More recently developed nanoparticles are demonstrating the potential sophistication of these delivery systems by incorporating multifunctional capabilities and targeting strategies in an effort to increase the efficacy of these systems against the most difficult cancer challenges, including drug resistance and metastatic disease. In this chapter, we will review the available preclinical and clinical nanoparticle technology platforms and their impact for cancer therapy.


Nanoparticle Drug delivery Targeted Metastatic cancer Cancer therapy